Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease

Cytokine

Volumn 69, Issue 2, 2014, Pages 294-297

  Zingone, Adriana ^a   Wang, Weixin ^b   Corrigan Cummins, Meghan ^b   Wu, S Peter ^a   Plyler, Ryan ^b   Korde, Neha ^a   Kwok, Mary ^a   Manasanch, Elisabet E ^a   Tageja, Nishant ^a   Bhutani, Manisha ^a   Mulquin, Marcia ^a   Zuchlinski, Diamond ^a   Yancey, Mary Ann ^a   Roschewski, Mark ^a   Zhang, Yong ^c   Roccaro, Aldo M ^c   Ghobrial, Irene M ^c   Calvo, Katherine R ^b   Landgren, Ola ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemokines; CXCL8; Multiple myeloma

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD ANALYSIS; BONE MARROW; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOLDERING MULTIPLE MYELOMA; TUMOR GROWTH; BLOOD;

CHEMOKINES; DISEASE PROGRESSION; HUMANS; MULTIPLE MYELOMA;

EID: 84938421348     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.05.017     Document Type: Article

References (15)

1. Kyle R.A., Durie B.G., Rajkumar S.V., Landgren O., Blade J., Merlini G., et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24(6):1121-1127.
2. Zingone A., Kuehl W.M. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011, 48(1):4-12.
3. Cherry B.M., Korde N., Kwok M., Manasanch E.E., Bhutani M., Mulquin M., et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013, 54(10):2215-2218.
4. Manier S., Sacco A., Leleu X., Ghobrial I.M., Roccaro A.M. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012, 2012:157496.
5. Kline M., Donovan K., Wellik L., Lust C., Jin W., Moon-Tasson L., et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007, 31(5):591-598.
6. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008 Nov 1, 14(21):6735-6741.
7. Holmes W.E., Lee J., Kuang W.J., Rice G.C., Wood W.I. Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253(5025):1278-1280.
8. Knall C., Worthen G.S., Johnson G.L. Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases. Proc Natl Acad Sci USA 1997, 94(7):3052-3057.
9. Schraufstatter I.U., Trieu K., Zhao M., Rose D.M., Terkeltaub R.A., Burger M. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol 2003, 171(12):6714-6722.
10. Petreaca M.L., Yao M., Liu Y., Defea K., Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 2007, 18(12):5014-5023.
11. Levina V., Marrangoni A.M., DeMarco R., Gorelik E., Lokshin A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3(8):e3077.
12. Maharaj L., Popat R., Gribben J.G., Joel S. IL-6, IL-8 and VEGF neutralisation restores drug sensitivity to conventional and novel treatment combinations in a multiple myeloma bone marrow micro-environment model. Blood 2012, 120(21). Abstract 2949.
13. Otsuki T., Yata K., Sakaguchi H., Uno M., Fujii T., Wada H., et al. IL-10 in myeloma cells. Leuk Lymphoma 2002, 43(5):969-974.
14. Hurt E.M., Wiestner A., Rosenwald A., Shaffer A.L., Campo E., Grogan T., et al. Overexpression of c-MAF is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004, 5(2):191-199.
15. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277(19):16639-16647.